DPP-4 Therapy Center

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.

Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.

Patients are not seeing the expected results because of medication adherence.

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.

Increased cardio risk of Saxagliptin found during trial prompts FDA decision.

The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.

We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.

A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.

DPP-4 Inhibitors offer some advantages over existing oral options for the management of type 2 diabetes such as a negligible risk of hypoglycemia compared with sulfonylureas and, in general, a weight-neutral profile.